Triumvira Immunologics is a technology company.
Triumvira Immunologics has raised $100.0M across 2 funding rounds.
Triumvira Immunologics has raised $100.0M in total across 2 funding rounds.
Triumvira Immunologics has raised $100.0M in total across 2 funding rounds.
Triumvira Immunologics's investors include B Capital Group, DFJ, Intuitive Ventures, Mithril Capital Management, Northpond Ventures, Sonder Capital.
Triumvira Immunologics is a clinical-stage immuno-oncology company developing non-gene edited T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform to treat solid tumors and certain liquid tumors.[1][2][3] The company builds autologous and allogeneic TAC-T cell therapeutics that co-opt natural T cell receptor signaling for precise tumor targeting with reduced toxicity, serving patients with cancers expressing antigens like Claudin 18.2, HER2, GUCY2C, and GPC3, such as gastric, gastroesophageal, colorectal, and HER2-positive solid tumors.[1][2][9] These therapies address key limitations of conventional CAR-T and engineered TCR therapies by enabling safer, re-dosable treatments with strong clinical signals, including a 70% disease control rate and 20% objective response rate in Claudin 18.2 trials.[2] With operations in San Diego, Austin, and Hamilton, Triumvira shows growth momentum through ongoing Phase I/II trials and data presentations at major symposia like ASCO 2025.[2][4]
Triumvira Immunologics emerged from expertise in T cell biology and cell therapy, though specific founding year and founders are not detailed in available sources; the company is anchored by a management team with deep experience in oncology drug development, manufacturing, and a strong IP portfolio.[1] The core idea stemmed from advancing T cell therapies beyond gene-edited approaches, leveraging the TAC platform to harness natural TCR signaling for better tumor recognition and killing in cancers where T cells fail.[3][8] Early traction includes preclinical success across multiple models and progression to clinical stages, with pivotal moments like updated Phase I/II data at the 2025 ASCO Gastrointestinal Cancers Symposium showing efficacy in heavily pretreated patients.[2][9]
Triumvira rides the solid tumor cell therapy wave, where CAR-T successes in blood cancers have spurred innovation for harder-to-treat solid tumors amid challenges like poor trafficking and immunosuppression.[3][4][8] Timing aligns with validated targets like Claudin 18.2—lacking approved therapies despite trial evidence of superior outcomes—and HER2, the top solid tumor CAR target with multiple competitors in clinic.[2][4][9] Market forces favoring precision immuno-oncology, including bispecifics and ADCs, boost TAC's edge in re-dosability and natural signaling, positioning Triumvira to influence the ecosystem by pioneering safer T cell platforms for broad cancer applicability.[1][2]
Triumvira is poised for pipeline expansion with multiple TAC candidates advancing, potentially yielding approvals for Claudin 18.2 and HER2 therapies in gastric and solid tumors where chemo falls short.[2][9] Trends like allogeneic scalability, combination regimens, and AI-optimized manufacturing will shape its path, amplifying influence as solid tumor cell therapy matures beyond CAR-T limitations.[3][4] Watch for more data readouts and partnerships to solidify its first-in-class status, transforming outcomes in high-need cancers.
Triumvira Immunologics has raised $100.0M across 2 funding rounds. Most recently, it raised $45.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2022 | $45.0M Series A | B Capital Group, DFJ, Intuitive Ventures, Mithril Capital Management, Northpond Ventures, Sonder Capital | |
| Aug 1, 2020 | $55.0M Series A | Northpond Ventures |